



TB Modelling and Analysis Consortium

Financing TB
Anna Vassall


TB funding increasing, primarily from domestic funding

Domestic funding is core to TB (84%), but comes primarily in the form of outpatient and inpatient care

BRICS funded 95% of their own TB services and 46% of global spending


Donor funding also increasing, but HIV funding and DAH staying stable. Critical for non-BRICS (48% of their funding)

Funding for TB prevention, diagnosis and treatment by funding source, 2006–2017, 118 countries with 97% of reported TB cases



^a Domestic funding includes TB-specific budgets and the estimated resources used for inpatient and outpatient care (see Box 6.1). 93% of the funding of US\$ 3 billion for inpatient and outpatient care in 2017 is accounted for by middle-income countries; such countries do not typically receive international donor funding for inpatient and outpatient care services.


Treatment outcomes for new and relapse TB cases^a (absolute numbers), 2000–2015, globally and for WHO regions



Financing (for UHC)

- Improve the amount of resources available and stability/sustainability
- Improve the equity of revenue raising
- Improve levels of risk-sharing/ pooling
- Improve the efficiency and equity of the allocation of resources (and eventually health outcomes)
- Support broader health sector aims such as responsiveness/ quality improvement


Simple Model




**Sources
(Collection)**

**Financing Agencies
(Pool and purchase)**

Providers



Domestic financing transition



Can we generate more funding for TB? Fiscal Space

Macro-economic and public revenues

GDP growth over next 5 years (IMF)

For countries with less than 25% of GDP public revenues, revenues increased to 25%

Borrowing up to 40% of government gross debt as a percentage of GDP

Earmarking (to health) alcohol tax (beer), assuming a price elasticity of demand of 0.3

Health Sector

Health spend for those countries up until 10% target


Convert 50% of OOP (above 20% of WHO acceptable level) to pooled funding under public purchasing, minus costs of pooling

TB Programme


Allocate funding to TB based on BoD (25%)

Improve cost of first line treatment to GDP weighted average (not norm)


Potential % increase in current TB expenditures - Macro




% Potential increase in current annual TB expenditures – Health



% Potential increase in current annual TB expenditures –TB



TB spend per case notified USD



Purchasing – benefit packages

- Assess disease burden, health challenges, priorities, health system capacity, including financing and UHC funding pool
- Agree on the goals and criteria for setting priorities
- Establish a process for dialogue and evidence-based deliberation on priorities
- Implement evidence based priority setting
- Identify barriers to implementation and identify needs to strengthen health system capacity
- Conduct detailed costing of the package
- Assess budget impact
- Establish monitoring and evaluation
- Set up longer term health technology assessment processes to review evidence and consider new technologies
- Links to strategic purchasing
- **3 Countries (Pakistan, Zambia, Rwanda, Senegal)**

UHC Benefit Package in Pakistan in Practice

Assessment

- Service descriptions based on local and WHO guidelines
- Populations in need and burden of disease revision
- Estimating local ballpark cost of all interventions prioritised in the review (normative, ingredients)
- Updating all DCP3 searches
- Transferability checklist of evidence quality
- Aggregation of cost and impact
- Other criteria
- Fiscal space WB/LSHTM
- Health systems assessment WHO

Appraisal

By end of this year



Government of Pakistan
Ministry of National Health Services,
Regulations & Coordination



Challenges for TB, but an opportunity

HBP


TB interventions 7 of top 10
IPT,FLT and DR-TB

BUT ALSO:

EQUITY

ALLOCATIONS BETWEEN SERVICE AND ABOVE SERVICE

INTEGRATED CARE (which packages)



Challenges from BP for TB modelling

- Engagement of range of stakeholders (decision processes - decentralization and finance/planning)
- Local capacity in costing and economic evaluation both within academic institutions and HPSIU
- Focusing analytical effort
 - Evidence quality and models
 - Arms race in evidence production
 - Transferability of effectiveness/epi models/ existing work – when to use models?